Sonnet biotherapeutics announces clinical trial of son-080 in patients with persistent chemotherapy-induced peripheral neuropathy

Sonnet's first clinical trial with son-080 is a phase 1b/2a double-blind, randomized controlled trial this trial is expected to provide safety data compared to previous il-6 products, along with preliminary efficacy recruitment initiated with dosing anticipated to begin imminently princeton, nj / accesswire / july 22, 2022 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a phase 1b/2a clinical trial of son-080 has been authorized to begin. this new study (sb211) will be conducted at multiple sites in australia in patients with persistent chemotherapy-induced peripheral neuropathy (cipn).
SONN Ratings Summary
SONN Quant Ranking